Background First-line nivolumab plus ipilimumab has shown improved overall survival in
patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate …

Background Nivolumab has shown improved survival in the treatment of advanced non-
small-cell lung cancer (NSCLC) previously treated with chemotherapy. We assessed the …

Background To further characterize survival benefit with first-line nivolumab plus ipilimumab
with two cycles of chemotherapy versus chemotherapy alone, we report updated data from …

Background In an early-phase study involving patients with advanced non–small-cell lung
cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with …

9016 Background: 1L NIVO+ IPI was shown to provide durable long-term overall survival
(OS) benefit vs chemo regardless of tumor programmed death ligand 1 (PD-L1) expression …

PURPOSE CheckMate 568 is an open-label phase II trial that evaluated the efficacy and
safety of nivolumab plus low-dose ipilimumab as first-line treatment of advanced/metastatic …

Objectives Nivolumab has recently received regulatory approval as a 2nd-line treatment of
non-small cell lung cancer (NSCLC). The data regarding its effectiveness and safety in real …

Purpose Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor antibody,
has demonstrated improved survival over docetaxel in previously treated advanced non …

Purpose Programmed death 1 is an immune checkpoint that suppresses antitumor immunity.
Nivolumab, a fully human immunoglobulin G4 programmed death 1 immune checkpoint …

Background Phase 3 clinical data has shown higher proportions of patients with objective
response, longer response duration, and longer overall survival with nivolumab versus …